nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—SIK1—dilated cardiomyopathy	0.677	1	CbGaD
Dasatinib—EPHA2—pulmonary artery—dilated cardiomyopathy	0.00483	0.0644	CbGeAlD
Dasatinib—Cytopenia—Lisinopril—dilated cardiomyopathy	0.00405	0.0514	CcSEcCtD
Dasatinib—Menstruation irregular—Spironolactone—dilated cardiomyopathy	0.00242	0.0308	CcSEcCtD
Dasatinib—TESK1—Enalapril—Lisinopril—dilated cardiomyopathy	0.00236	1	CbGdCrCtD
Dasatinib—Drug eruption—Spironolactone—dilated cardiomyopathy	0.00218	0.0277	CcSEcCtD
Dasatinib—Rash erythematous—Spironolactone—dilated cardiomyopathy	0.00175	0.0222	CcSEcCtD
Dasatinib—SIK3—myocardium—dilated cardiomyopathy	0.00163	0.0218	CbGeAlD
Dasatinib—Atrial flutter—Lisinopril—dilated cardiomyopathy	0.00144	0.0183	CcSEcCtD
Dasatinib—BMX—heart—dilated cardiomyopathy	0.00143	0.0191	CbGeAlD
Dasatinib—TESK1—myocardium—dilated cardiomyopathy	0.00134	0.0179	CbGeAlD
Dasatinib—STK35—cardiac ventricle—dilated cardiomyopathy	0.00132	0.0175	CbGeAlD
Dasatinib—CSK—cardiac ventricle—dilated cardiomyopathy	0.00131	0.0174	CbGeAlD
Dasatinib—STAT5B—heart—dilated cardiomyopathy	0.00127	0.0169	CbGeAlD
Dasatinib—STK35—myocardium—dilated cardiomyopathy	0.00124	0.0165	CbGeAlD
Dasatinib—CSK—myocardium—dilated cardiomyopathy	0.00123	0.0164	CbGeAlD
Dasatinib—HCK—myocardium—dilated cardiomyopathy	0.00121	0.0162	CbGeAlD
Dasatinib—Gynaecomastia—Spironolactone—dilated cardiomyopathy	0.0012	0.0152	CcSEcCtD
Dasatinib—Drug eruption—Furosemide—dilated cardiomyopathy	0.00119	0.0151	CcSEcCtD
Dasatinib—SIK1—cardiac ventricle—dilated cardiomyopathy	0.00118	0.0158	CbGeAlD
Dasatinib—EPHA3—heart—dilated cardiomyopathy	0.00117	0.0156	CbGeAlD
Dasatinib—Lung infiltration—Lisinopril—dilated cardiomyopathy	0.00117	0.0148	CcSEcCtD
Dasatinib—RIPK2—myocardium—dilated cardiomyopathy	0.00114	0.0152	CbGeAlD
Dasatinib—SIK3—heart—dilated cardiomyopathy	0.00114	0.0152	CbGeAlD
Dasatinib—SIK1—myocardium—dilated cardiomyopathy	0.00111	0.0149	CbGeAlD
Dasatinib—EPHA4—myocardium—dilated cardiomyopathy	0.0011	0.0147	CbGeAlD
Dasatinib—Transient ischaemic attack—Lisinopril—dilated cardiomyopathy	0.00109	0.0138	CcSEcCtD
Dasatinib—ZAK—heart—dilated cardiomyopathy	0.00106	0.0141	CbGeAlD
Dasatinib—Thrombosis—Furosemide—dilated cardiomyopathy	0.00103	0.0131	CcSEcCtD
Dasatinib—EPHB4—cardiac ventricle—dilated cardiomyopathy	0.00102	0.0137	CbGeAlD
Dasatinib—JAK2—cardiac ventricle—dilated cardiomyopathy	0.00102	0.0136	CbGeAlD
Dasatinib—FYN—cardiac ventricle—dilated cardiomyopathy	0.001	0.0134	CbGeAlD
Dasatinib—TNK2—heart—dilated cardiomyopathy	0.000996	0.0133	CbGeAlD
Dasatinib—MAP3K3—cardiac ventricle—dilated cardiomyopathy	0.000981	0.0131	CbGeAlD
Dasatinib—SIK3—cardiac atrium—dilated cardiomyopathy	0.000975	0.013	CbGeAlD
Dasatinib—EPHB4—myocardium—dilated cardiomyopathy	0.000964	0.0128	CbGeAlD
Dasatinib—Cholestasis—Furosemide—dilated cardiomyopathy	0.000961	0.0122	CcSEcCtD
Dasatinib—JAK2—myocardium—dilated cardiomyopathy	0.000957	0.0128	CbGeAlD
Dasatinib—FYN—myocardium—dilated cardiomyopathy	0.000944	0.0126	CbGeAlD
Dasatinib—TESK1—heart—dilated cardiomyopathy	0.000936	0.0125	CbGeAlD
Dasatinib—MAP3K3—myocardium—dilated cardiomyopathy	0.000922	0.0123	CbGeAlD
Dasatinib—STK36—heart—dilated cardiomyopathy	0.000922	0.0123	CbGeAlD
Dasatinib—EPHB3—heart—dilated cardiomyopathy	0.000922	0.0123	CbGeAlD
Dasatinib—Generalised oedema—Lisinopril—dilated cardiomyopathy	0.000921	0.0117	CcSEcCtD
Dasatinib—YES1—cardiac ventricle—dilated cardiomyopathy	0.000906	0.0121	CbGeAlD
Dasatinib—LIMK2—heart—dilated cardiomyopathy	0.000891	0.0119	CbGeAlD
Dasatinib—STK35—heart—dilated cardiomyopathy	0.000864	0.0115	CbGeAlD
Dasatinib—Gastritis—Spironolactone—dilated cardiomyopathy	0.000862	0.0109	CcSEcCtD
Dasatinib—CSK—heart—dilated cardiomyopathy	0.000858	0.0114	CbGeAlD
Dasatinib—YES1—myocardium—dilated cardiomyopathy	0.000852	0.0114	CbGeAlD
Dasatinib—HCK—heart—dilated cardiomyopathy	0.000847	0.0113	CbGeAlD
Dasatinib—ABL2—heart—dilated cardiomyopathy	0.000842	0.0112	CbGeAlD
Dasatinib—TESK1—cardiac atrium—dilated cardiomyopathy	0.000801	0.0107	CbGeAlD
Dasatinib—Hypocalcaemia—Furosemide—dilated cardiomyopathy	0.000798	0.0101	CcSEcCtD
Dasatinib—RIPK2—heart—dilated cardiomyopathy	0.000796	0.0106	CbGeAlD
Dasatinib—Hyperuricaemia—Furosemide—dilated cardiomyopathy	0.000787	0.00999	CcSEcCtD
Dasatinib—SIK1—heart—dilated cardiomyopathy	0.000777	0.0104	CbGeAlD
Dasatinib—EPHA4—heart—dilated cardiomyopathy	0.00077	0.0103	CbGeAlD
Dasatinib—ERBB3—heart—dilated cardiomyopathy	0.000762	0.0102	CbGeAlD
Dasatinib—MAP3K2—heart—dilated cardiomyopathy	0.000755	0.0101	CbGeAlD
Dasatinib—MAP2K5—myocardium—dilated cardiomyopathy	0.000754	0.0101	CbGeAlD
Dasatinib—Blood uric acid increased—Furosemide—dilated cardiomyopathy	0.000743	0.00944	CcSEcCtD
Dasatinib—Haemoptysis—Lisinopril—dilated cardiomyopathy	0.00074	0.0094	CcSEcCtD
Dasatinib—STK35—cardiac atrium—dilated cardiomyopathy	0.000739	0.00985	CbGeAlD
Dasatinib—Renal failure—Spironolactone—dilated cardiomyopathy	0.000738	0.00937	CcSEcCtD
Dasatinib—CSK—cardiac atrium—dilated cardiomyopathy	0.000734	0.00978	CbGeAlD
Dasatinib—Pleural effusion—Lisinopril—dilated cardiomyopathy	0.000715	0.00908	CcSEcCtD
Dasatinib—MAPK14—heart—dilated cardiomyopathy	0.00071	0.00946	CbGeAlD
Dasatinib—FGR—heart—dilated cardiomyopathy	0.000707	0.00942	CbGeAlD
Dasatinib—LCK—heart—dilated cardiomyopathy	0.000707	0.00942	CbGeAlD
Dasatinib—PDGFRB—cardiac ventricle—dilated cardiomyopathy	0.000694	0.00925	CbGeAlD
Dasatinib—FMO3—heart—dilated cardiomyopathy	0.000683	0.0091	CbGeAlD
Dasatinib—RIPK2—cardiac atrium—dilated cardiomyopathy	0.000681	0.00908	CbGeAlD
Dasatinib—EPHB4—heart—dilated cardiomyopathy	0.000673	0.00897	CbGeAlD
Dasatinib—KIT—myocardium—dilated cardiomyopathy	0.000668	0.00891	CbGeAlD
Dasatinib—JAK2—heart—dilated cardiomyopathy	0.000668	0.00891	CbGeAlD
Dasatinib—SIK1—cardiac atrium—dilated cardiomyopathy	0.000665	0.00887	CbGeAlD
Dasatinib—EPHA2—heart—dilated cardiomyopathy	0.00066	0.0088	CbGeAlD
Dasatinib—FYN—heart—dilated cardiomyopathy	0.000659	0.00878	CbGeAlD
Dasatinib—EPHA4—cardiac atrium—dilated cardiomyopathy	0.000658	0.00878	CbGeAlD
Dasatinib—PDGFRB—myocardium—dilated cardiomyopathy	0.000652	0.0087	CbGeAlD
Dasatinib—MAP3K3—heart—dilated cardiomyopathy	0.000644	0.00858	CbGeAlD
Dasatinib—MAP4K5—heart—dilated cardiomyopathy	0.000644	0.00858	CbGeAlD
Dasatinib—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.000637	0.00809	CcSEcCtD
Dasatinib—Proteinuria—Lisinopril—dilated cardiomyopathy	0.000623	0.00791	CcSEcCtD
Dasatinib—ABL1—cardiac ventricle—dilated cardiomyopathy	0.000618	0.00824	CbGeAlD
Dasatinib—EPHB6—heart—dilated cardiomyopathy	0.000615	0.0082	CbGeAlD
Dasatinib—Protein urine present—Lisinopril—dilated cardiomyopathy	0.000615	0.00781	CcSEcCtD
Dasatinib—Thrombophlebitis—Furosemide—dilated cardiomyopathy	0.000612	0.00777	CcSEcCtD
Dasatinib—Photosensitivity—Furosemide—dilated cardiomyopathy	0.000604	0.00766	CcSEcCtD
Dasatinib—Alopecia—Spironolactone—dilated cardiomyopathy	0.000595	0.00756	CcSEcCtD
Dasatinib—YES1—heart—dilated cardiomyopathy	0.000595	0.00793	CbGeAlD
Dasatinib—PDGFRA—heart—dilated cardiomyopathy	0.000583	0.00778	CbGeAlD
Dasatinib—ABL1—myocardium—dilated cardiomyopathy	0.000582	0.00775	CbGeAlD
Dasatinib—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.000575	0.00731	CcSEcCtD
Dasatinib—EPHB4—cardiac atrium—dilated cardiomyopathy	0.000575	0.00767	CbGeAlD
Dasatinib—SRC—heart—dilated cardiomyopathy	0.000572	0.00763	CbGeAlD
Dasatinib—JAK2—cardiac atrium—dilated cardiomyopathy	0.000571	0.00762	CbGeAlD
Dasatinib—EPHA2—cardiac atrium—dilated cardiomyopathy	0.000564	0.00753	CbGeAlD
Dasatinib—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.000564	0.00716	CcSEcCtD
Dasatinib—FYN—cardiac atrium—dilated cardiomyopathy	0.000563	0.00751	CbGeAlD
Dasatinib—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.000554	0.00704	CcSEcCtD
Dasatinib—MAP4K5—cardiac atrium—dilated cardiomyopathy	0.000551	0.00734	CbGeAlD
Dasatinib—MAP3K3—cardiac atrium—dilated cardiomyopathy	0.000551	0.00734	CbGeAlD
Dasatinib—Ventricular tachycardia—Lisinopril—dilated cardiomyopathy	0.000548	0.00695	CcSEcCtD
Dasatinib—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.000548	0.00695	CcSEcCtD
Dasatinib—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.000544	0.00691	CcSEcCtD
Dasatinib—Malaise—Spironolactone—dilated cardiomyopathy	0.000529	0.00672	CcSEcCtD
Dasatinib—EPHB6—cardiac atrium—dilated cardiomyopathy	0.000526	0.00702	CbGeAlD
Dasatinib—MAP2K5—heart—dilated cardiomyopathy	0.000526	0.00702	CbGeAlD
Dasatinib—Fluid retention—Lisinopril—dilated cardiomyopathy	0.00052	0.0066	CcSEcCtD
Dasatinib—Neuropathy—Lisinopril—dilated cardiomyopathy	0.000514	0.00653	CcSEcCtD
Dasatinib—CSF1R—heart—dilated cardiomyopathy	0.000514	0.00685	CbGeAlD
Dasatinib—YES1—cardiac atrium—dilated cardiomyopathy	0.000509	0.00678	CbGeAlD
Dasatinib—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.000496	0.0063	CcSEcCtD
Dasatinib—Discomfort—Spironolactone—dilated cardiomyopathy	0.000493	0.00626	CcSEcCtD
Dasatinib—SRC—cardiac atrium—dilated cardiomyopathy	0.000489	0.00652	CbGeAlD
Dasatinib—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.000488	0.00619	CcSEcCtD
Dasatinib—Confusional state—Spironolactone—dilated cardiomyopathy	0.000483	0.00613	CcSEcCtD
Dasatinib—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.000482	0.00612	CcSEcCtD
Dasatinib—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.000469	0.00595	CcSEcCtD
Dasatinib—Muscular weakness—Furosemide—dilated cardiomyopathy	0.000467	0.00593	CcSEcCtD
Dasatinib—KIT—heart—dilated cardiomyopathy	0.000466	0.00622	CbGeAlD
Dasatinib—Abdominal distension—Furosemide—dilated cardiomyopathy	0.000461	0.00585	CcSEcCtD
Dasatinib—PDGFRB—heart—dilated cardiomyopathy	0.000455	0.00607	CbGeAlD
Dasatinib—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.000453	0.00575	CcSEcCtD
Dasatinib—MAP2K5—cardiac atrium—dilated cardiomyopathy	0.00045	0.006	CbGeAlD
Dasatinib—Pancreatitis—Furosemide—dilated cardiomyopathy	0.000449	0.0057	CcSEcCtD
Dasatinib—Eczema—Lisinopril—dilated cardiomyopathy	0.000442	0.00562	CcSEcCtD
Dasatinib—CSF1R—cardiac atrium—dilated cardiomyopathy	0.000439	0.00586	CbGeAlD
Dasatinib—Libido decreased—Lisinopril—dilated cardiomyopathy	0.000429	0.00544	CcSEcCtD
Dasatinib—Somnolence—Spironolactone—dilated cardiomyopathy	0.000426	0.0054	CcSEcCtD
Dasatinib—Pollakiuria—Furosemide—dilated cardiomyopathy	0.000423	0.00537	CcSEcCtD
Dasatinib—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.00042	0.00533	CcSEcCtD
Dasatinib—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.000418	0.00531	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000413	0.00525	CcSEcCtD
Dasatinib—ABL1—heart—dilated cardiomyopathy	0.000406	0.00541	CbGeAlD
Dasatinib—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.000406	0.00515	CcSEcCtD
Dasatinib—Renal failure—Furosemide—dilated cardiomyopathy	0.000401	0.0051	CcSEcCtD
Dasatinib—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.000395	0.00501	CcSEcCtD
Dasatinib—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.000394	0.00501	CcSEcCtD
Dasatinib—PDGFRB—cardiac atrium—dilated cardiomyopathy	0.00039	0.00519	CbGeAlD
Dasatinib—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.000386	0.0049	CcSEcCtD
Dasatinib—Face oedema—Lisinopril—dilated cardiomyopathy	0.000384	0.00487	CcSEcCtD
Dasatinib—Urticaria—Spironolactone—dilated cardiomyopathy	0.00038	0.00483	CcSEcCtD
Dasatinib—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000378	0.0048	CcSEcCtD
Dasatinib—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.000373	0.00473	CcSEcCtD
Dasatinib—CYP1A1—cardiac ventricle—dilated cardiomyopathy	0.00037	0.00493	CbGeAlD
Dasatinib—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.000362	0.0046	CcSEcCtD
Dasatinib—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000359	0.00456	CcSEcCtD
Dasatinib—Breast disorder—Lisinopril—dilated cardiomyopathy	0.000359	0.00456	CcSEcCtD
Dasatinib—Visual impairment—Furosemide—dilated cardiomyopathy	0.000353	0.00449	CcSEcCtD
Dasatinib—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000353	0.00448	CcSEcCtD
Dasatinib—Gastritis—Lisinopril—dilated cardiomyopathy	0.000352	0.00447	CcSEcCtD
Dasatinib—ABL1—cardiac atrium—dilated cardiomyopathy	0.000347	0.00463	CbGeAlD
Dasatinib—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.000347	0.0044	CcSEcCtD
Dasatinib—CYP1B1—heart—dilated cardiomyopathy	0.000344	0.00458	CbGeAlD
Dasatinib—Asthma—Lisinopril—dilated cardiomyopathy	0.000344	0.00436	CcSEcCtD
Dasatinib—Eye disorder—Furosemide—dilated cardiomyopathy	0.000343	0.00435	CcSEcCtD
Dasatinib—Tinnitus—Furosemide—dilated cardiomyopathy	0.000342	0.00434	CcSEcCtD
Dasatinib—Pruritus—Spironolactone—dilated cardiomyopathy	0.000339	0.0043	CcSEcCtD
Dasatinib—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.000338	0.00429	CcSEcCtD
Dasatinib—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.000337	0.00428	CcSEcCtD
Dasatinib—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.000335	0.00425	CcSEcCtD
Dasatinib—Angiopathy—Furosemide—dilated cardiomyopathy	0.000333	0.00422	CcSEcCtD
Dasatinib—Immune system disorder—Furosemide—dilated cardiomyopathy	0.000331	0.0042	CcSEcCtD
Dasatinib—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000328	0.00416	CcSEcCtD
Dasatinib—Arrhythmia—Furosemide—dilated cardiomyopathy	0.000328	0.00416	CcSEcCtD
Dasatinib—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.000326	0.00414	CcSEcCtD
Dasatinib—Neutropenia—Lisinopril—dilated cardiomyopathy	0.000321	0.00408	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.000319	0.00406	CcSEcCtD
Dasatinib—Malnutrition—Furosemide—dilated cardiomyopathy	0.000319	0.00405	CcSEcCtD
Dasatinib—Erythema—Furosemide—dilated cardiomyopathy	0.000319	0.00405	CcSEcCtD
Dasatinib—Dizziness—Spironolactone—dilated cardiomyopathy	0.000317	0.00402	CcSEcCtD
Dasatinib—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.000314	0.00398	CcSEcCtD
Dasatinib—Weight increased—Lisinopril—dilated cardiomyopathy	0.000313	0.00397	CcSEcCtD
Dasatinib—Dysgeusia—Furosemide—dilated cardiomyopathy	0.000313	0.00397	CcSEcCtD
Dasatinib—Weight decreased—Lisinopril—dilated cardiomyopathy	0.000311	0.00395	CcSEcCtD
Dasatinib—Pneumonia—Lisinopril—dilated cardiomyopathy	0.000308	0.00391	CcSEcCtD
Dasatinib—Muscle spasms—Furosemide—dilated cardiomyopathy	0.000307	0.0039	CcSEcCtD
Dasatinib—Vomiting—Spironolactone—dilated cardiomyopathy	0.000304	0.00386	CcSEcCtD
Dasatinib—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.000302	0.00384	CcSEcCtD
Dasatinib—Rash—Spironolactone—dilated cardiomyopathy	0.000302	0.00383	CcSEcCtD
Dasatinib—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000302	0.00383	CcSEcCtD
Dasatinib—Renal failure—Lisinopril—dilated cardiomyopathy	0.000301	0.00382	CcSEcCtD
Dasatinib—Vision blurred—Furosemide—dilated cardiomyopathy	0.000301	0.00382	CcSEcCtD
Dasatinib—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.0003	0.00381	CcSEcCtD
Dasatinib—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.0003	0.00381	CcSEcCtD
Dasatinib—Headache—Spironolactone—dilated cardiomyopathy	0.0003	0.00381	CcSEcCtD
Dasatinib—Anaemia—Furosemide—dilated cardiomyopathy	0.000295	0.00375	CcSEcCtD
Dasatinib—Haematuria—Lisinopril—dilated cardiomyopathy	0.000292	0.00371	CcSEcCtD
Dasatinib—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00029	0.00368	CcSEcCtD
Dasatinib—Epistaxis—Lisinopril—dilated cardiomyopathy	0.000289	0.00367	CcSEcCtD
Dasatinib—Vertigo—Furosemide—dilated cardiomyopathy	0.000287	0.00364	CcSEcCtD
Dasatinib—Nausea—Spironolactone—dilated cardiomyopathy	0.000284	0.00361	CcSEcCtD
Dasatinib—Hepatitis—Lisinopril—dilated cardiomyopathy	0.000275	0.00349	CcSEcCtD
Dasatinib—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000272	0.00345	CcSEcCtD
Dasatinib—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000271	0.00344	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00027	0.00343	CcSEcCtD
Dasatinib—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00027	0.00342	CcSEcCtD
Dasatinib—Confusional state—Furosemide—dilated cardiomyopathy	0.000263	0.00333	CcSEcCtD
Dasatinib—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00026	0.0033	CcSEcCtD
Dasatinib—Tinnitus—Lisinopril—dilated cardiomyopathy	0.000256	0.00326	CcSEcCtD
Dasatinib—Shock—Furosemide—dilated cardiomyopathy	0.000256	0.00325	CcSEcCtD
Dasatinib—ABCG2—heart—dilated cardiomyopathy	0.000256	0.00341	CbGeAlD
Dasatinib—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000255	0.00324	CcSEcCtD
Dasatinib—Flushing—Lisinopril—dilated cardiomyopathy	0.000255	0.00324	CcSEcCtD
Dasatinib—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000255	0.00324	CcSEcCtD
Dasatinib—Skin disorder—Furosemide—dilated cardiomyopathy	0.000253	0.00321	CcSEcCtD
Dasatinib—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000252	0.0032	CcSEcCtD
Dasatinib—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00025	0.00317	CcSEcCtD
Dasatinib—Anorexia—Furosemide—dilated cardiomyopathy	0.000248	0.00315	CcSEcCtD
Dasatinib—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000248	0.00315	CcSEcCtD
Dasatinib—Chills—Lisinopril—dilated cardiomyopathy	0.000247	0.00313	CcSEcCtD
Dasatinib—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.000246	0.00312	CcSEcCtD
Dasatinib—Hypotension—Furosemide—dilated cardiomyopathy	0.000243	0.00309	CcSEcCtD
Dasatinib—Alopecia—Lisinopril—dilated cardiomyopathy	0.000243	0.00309	CcSEcCtD
Dasatinib—CYP1A1—heart—dilated cardiomyopathy	0.000243	0.00324	CbGeAlD
Dasatinib—Mental disorder—Lisinopril—dilated cardiomyopathy	0.000241	0.00306	CcSEcCtD
Dasatinib—Erythema—Lisinopril—dilated cardiomyopathy	0.000239	0.00304	CcSEcCtD
Dasatinib—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000239	0.00304	CcSEcCtD
Dasatinib—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000235	0.00298	CcSEcCtD
Dasatinib—Somnolence—Furosemide—dilated cardiomyopathy	0.000232	0.00294	CcSEcCtD
Dasatinib—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00023	0.00292	CcSEcCtD
Dasatinib—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000226	0.00287	CcSEcCtD
Dasatinib—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000226	0.00287	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000225	0.00285	CcSEcCtD
Dasatinib—Fatigue—Furosemide—dilated cardiomyopathy	0.000225	0.00285	CcSEcCtD
Dasatinib—Tremor—Lisinopril—dilated cardiomyopathy	0.000224	0.00285	CcSEcCtD
Dasatinib—Pain—Furosemide—dilated cardiomyopathy	0.000223	0.00283	CcSEcCtD
Dasatinib—Constipation—Furosemide—dilated cardiomyopathy	0.000223	0.00283	CcSEcCtD
Dasatinib—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.000222	0.00282	CcSEcCtD
Dasatinib—Anaemia—Lisinopril—dilated cardiomyopathy	0.000221	0.00281	CcSEcCtD
Dasatinib—Malaise—Lisinopril—dilated cardiomyopathy	0.000216	0.00274	CcSEcCtD
Dasatinib—Vertigo—Lisinopril—dilated cardiomyopathy	0.000215	0.00273	CcSEcCtD
Dasatinib—Syncope—Lisinopril—dilated cardiomyopathy	0.000215	0.00273	CcSEcCtD
Dasatinib—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000215	0.00273	CcSEcCtD
Dasatinib—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000213	0.0027	CcSEcCtD
Dasatinib—Palpitations—Lisinopril—dilated cardiomyopathy	0.000212	0.00269	CcSEcCtD
Dasatinib—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00021	0.00267	CcSEcCtD
Dasatinib—Cough—Lisinopril—dilated cardiomyopathy	0.000209	0.00265	CcSEcCtD
Dasatinib—CYP1A1—cardiac atrium—dilated cardiomyopathy	0.000208	0.00277	CbGeAlD
Dasatinib—Urticaria—Furosemide—dilated cardiomyopathy	0.000207	0.00263	CcSEcCtD
Dasatinib—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000206	0.00261	CcSEcCtD
Dasatinib—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000206	0.00261	CcSEcCtD
Dasatinib—Chest pain—Lisinopril—dilated cardiomyopathy	0.000204	0.00259	CcSEcCtD
Dasatinib—Myalgia—Lisinopril—dilated cardiomyopathy	0.000204	0.00259	CcSEcCtD
Dasatinib—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000204	0.00259	CcSEcCtD
Dasatinib—Anxiety—Lisinopril—dilated cardiomyopathy	0.000203	0.00258	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000202	0.00257	CcSEcCtD
Dasatinib—Discomfort—Lisinopril—dilated cardiomyopathy	0.000201	0.00256	CcSEcCtD
Dasatinib—Confusional state—Lisinopril—dilated cardiomyopathy	0.000197	0.0025	CcSEcCtD
Dasatinib—Oedema—Lisinopril—dilated cardiomyopathy	0.000195	0.00248	CcSEcCtD
Dasatinib—Infection—Lisinopril—dilated cardiomyopathy	0.000194	0.00246	CcSEcCtD
Dasatinib—Shock—Lisinopril—dilated cardiomyopathy	0.000192	0.00244	CcSEcCtD
Dasatinib—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000192	0.00244	CcSEcCtD
Dasatinib—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000191	0.00243	CcSEcCtD
Dasatinib—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000191	0.00242	CcSEcCtD
Dasatinib—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00019	0.00241	CcSEcCtD
Dasatinib—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000189	0.0024	CcSEcCtD
Dasatinib—Asthenia—Furosemide—dilated cardiomyopathy	0.000187	0.00237	CcSEcCtD
Dasatinib—Anorexia—Lisinopril—dilated cardiomyopathy	0.000186	0.00237	CcSEcCtD
Dasatinib—Pruritus—Furosemide—dilated cardiomyopathy	0.000184	0.00234	CcSEcCtD
Dasatinib—Hypotension—Lisinopril—dilated cardiomyopathy	0.000183	0.00232	CcSEcCtD
Dasatinib—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000178	0.00226	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000178	0.00226	CcSEcCtD
Dasatinib—Insomnia—Lisinopril—dilated cardiomyopathy	0.000177	0.00224	CcSEcCtD
Dasatinib—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000174	0.00221	CcSEcCtD
Dasatinib—Somnolence—Lisinopril—dilated cardiomyopathy	0.000174	0.00221	CcSEcCtD
Dasatinib—Dizziness—Furosemide—dilated cardiomyopathy	0.000172	0.00219	CcSEcCtD
Dasatinib—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000172	0.00218	CcSEcCtD
Dasatinib—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00017	0.00216	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000169	0.00214	CcSEcCtD
Dasatinib—Fatigue—Lisinopril—dilated cardiomyopathy	0.000168	0.00214	CcSEcCtD
Dasatinib—Pain—Lisinopril—dilated cardiomyopathy	0.000167	0.00212	CcSEcCtD
Dasatinib—Constipation—Lisinopril—dilated cardiomyopathy	0.000167	0.00212	CcSEcCtD
Dasatinib—Vomiting—Furosemide—dilated cardiomyopathy	0.000166	0.0021	CcSEcCtD
Dasatinib—Rash—Furosemide—dilated cardiomyopathy	0.000164	0.00209	CcSEcCtD
Dasatinib—Dermatitis—Furosemide—dilated cardiomyopathy	0.000164	0.00208	CcSEcCtD
Dasatinib—Headache—Furosemide—dilated cardiomyopathy	0.000163	0.00207	CcSEcCtD
Dasatinib—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000161	0.00204	CcSEcCtD
Dasatinib—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00016	0.00203	CcSEcCtD
Dasatinib—Urticaria—Lisinopril—dilated cardiomyopathy	0.000155	0.00197	CcSEcCtD
Dasatinib—Nausea—Furosemide—dilated cardiomyopathy	0.000155	0.00196	CcSEcCtD
Dasatinib—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000154	0.00196	CcSEcCtD
Dasatinib—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000154	0.00196	CcSEcCtD
Dasatinib—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000144	0.00183	CcSEcCtD
Dasatinib—Asthenia—Lisinopril—dilated cardiomyopathy	0.00014	0.00178	CcSEcCtD
Dasatinib—Pruritus—Lisinopril—dilated cardiomyopathy	0.000138	0.00176	CcSEcCtD
Dasatinib—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000134	0.0017	CcSEcCtD
Dasatinib—Dizziness—Lisinopril—dilated cardiomyopathy	0.000129	0.00164	CcSEcCtD
Dasatinib—ABCB1—heart—dilated cardiomyopathy	0.000126	0.00168	CbGeAlD
Dasatinib—Vomiting—Lisinopril—dilated cardiomyopathy	0.000124	0.00158	CcSEcCtD
Dasatinib—Rash—Lisinopril—dilated cardiomyopathy	0.000123	0.00156	CcSEcCtD
Dasatinib—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000123	0.00156	CcSEcCtD
Dasatinib—Headache—Lisinopril—dilated cardiomyopathy	0.000122	0.00155	CcSEcCtD
Dasatinib—Nausea—Lisinopril—dilated cardiomyopathy	0.000116	0.00147	CcSEcCtD
Dasatinib—STAT5B—Immune System—EGFR—dilated cardiomyopathy	5.78e-06	3.46e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PSEN2—dilated cardiomyopathy	5.77e-06	3.45e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.75e-06	3.44e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.75e-06	3.44e-05	CbGpPWpGaD
Dasatinib—YES1—Innate Immune System—EGFR—dilated cardiomyopathy	5.73e-06	3.43e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—RAC1—dilated cardiomyopathy	5.73e-06	3.43e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CXCR3—dilated cardiomyopathy	5.72e-06	3.42e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—CD36—dilated cardiomyopathy	5.72e-06	3.42e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—RAF1—dilated cardiomyopathy	5.67e-06	3.39e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.63e-06	3.37e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—RAF1—dilated cardiomyopathy	5.62e-06	3.36e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—RAC1—dilated cardiomyopathy	5.61e-06	3.36e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—RAC1—dilated cardiomyopathy	5.61e-06	3.35e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—RAC1—dilated cardiomyopathy	5.59e-06	3.34e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—ITGB1—dilated cardiomyopathy	5.58e-06	3.34e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	5.57e-06	3.33e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—RAF1—dilated cardiomyopathy	5.55e-06	3.32e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.54e-06	3.31e-05	CbGpPWpGaD
Dasatinib—CSK—Disease—EGFR—dilated cardiomyopathy	5.51e-06	3.29e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CXCR3—dilated cardiomyopathy	5.51e-06	3.29e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—CD36—dilated cardiomyopathy	5.51e-06	3.29e-05	CbGpPWpGaD
Dasatinib—YES1—Adaptive Immune System—EGFR—dilated cardiomyopathy	5.5e-06	3.29e-05	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—EGFR—dilated cardiomyopathy	5.47e-06	3.27e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—RAC1—dilated cardiomyopathy	5.47e-06	3.27e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.46e-06	3.27e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—RAC1—dilated cardiomyopathy	5.45e-06	3.26e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—RAF1—dilated cardiomyopathy	5.45e-06	3.26e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.45e-06	3.26e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling by NGF—EGFR—dilated cardiomyopathy	5.44e-06	3.25e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CXCR3—dilated cardiomyopathy	5.44e-06	3.25e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—CD36—dilated cardiomyopathy	5.44e-06	3.25e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	5.42e-06	3.24e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—RAC1—dilated cardiomyopathy	5.41e-06	3.23e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—RAC1—dilated cardiomyopathy	5.39e-06	3.22e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—AGT—dilated cardiomyopathy	5.36e-06	3.21e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—AGT—dilated cardiomyopathy	5.36e-06	3.2e-05	CbGpPWpGaD
Dasatinib—STAT5B—Disease—EGFR—dilated cardiomyopathy	5.33e-06	3.19e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.33e-06	3.19e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	5.28e-06	3.16e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.27e-06	3.15e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.25e-06	3.14e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—RAC1—dilated cardiomyopathy	5.19e-06	3.1e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—ADRB2—dilated cardiomyopathy	5.17e-06	3.09e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AGT—dilated cardiomyopathy	5.17e-06	3.09e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—RAC1—dilated cardiomyopathy	5.16e-06	3.09e-05	CbGpPWpGaD
Dasatinib—MAP3K3—Immune System—EGFR—dilated cardiomyopathy	5.13e-06	3.07e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—RAC1—dilated cardiomyopathy	5.12e-06	3.06e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.12e-06	3.06e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.12e-06	3.06e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—RAF1—dilated cardiomyopathy	5.12e-06	3.06e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—RAF1—dilated cardiomyopathy	5.12e-06	3.06e-05	CbGpPWpGaD
Dasatinib—KIT—Innate Immune System—EGFR—dilated cardiomyopathy	5.12e-06	3.06e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—RAF1—dilated cardiomyopathy	5.11e-06	3.06e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PSEN2—dilated cardiomyopathy	5.11e-06	3.05e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—RAF1—dilated cardiomyopathy	5.02e-06	3e-05	CbGpPWpGaD
Dasatinib—BTK—Immune System—EGFR—dilated cardiomyopathy	4.99e-06	2.99e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—RAC1—dilated cardiomyopathy	4.98e-06	2.98e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	4.96e-06	2.97e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—ITGB1—dilated cardiomyopathy	4.94e-06	2.96e-05	CbGpPWpGaD
Dasatinib—SRC—Axon guidance—EGFR—dilated cardiomyopathy	4.92e-06	2.94e-05	CbGpPWpGaD
Dasatinib—KIT—Adaptive Immune System—EGFR—dilated cardiomyopathy	4.91e-06	2.94e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.91e-06	2.94e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—RAF1—dilated cardiomyopathy	4.9e-06	2.93e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	4.88e-06	2.92e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—RAF1—dilated cardiomyopathy	4.87e-06	2.91e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Innate Immune System—EGFR—dilated cardiomyopathy	4.84e-06	2.9e-05	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—EGFR—dilated cardiomyopathy	4.84e-06	2.89e-05	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—EGFR—dilated cardiomyopathy	4.82e-06	2.88e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.8e-06	2.87e-05	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—EGFR—dilated cardiomyopathy	4.76e-06	2.85e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.76e-06	2.85e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—CD36—dilated cardiomyopathy	4.76e-06	2.85e-05	CbGpPWpGaD
Dasatinib—ABCG2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	4.76e-06	2.85e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—RAC1—dilated cardiomyopathy	4.75e-06	2.84e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.73e-06	2.83e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—RAC1—dilated cardiomyopathy	4.73e-06	2.83e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.69e-06	2.81e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.66e-06	2.78e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Adaptive Immune System—EGFR—dilated cardiomyopathy	4.65e-06	2.78e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.61e-06	2.76e-05	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—TNF—dilated cardiomyopathy	4.61e-06	2.76e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—EGFR—dilated cardiomyopathy	4.59e-06	2.74e-05	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—TNF—dilated cardiomyopathy	4.59e-06	2.74e-05	CbGpPWpGaD
Dasatinib—HCK—Immune System—EGFR—dilated cardiomyopathy	4.58e-06	2.74e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.56e-06	2.73e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.56e-06	2.72e-05	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—TNF—dilated cardiomyopathy	4.54e-06	2.71e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AGT—dilated cardiomyopathy	4.53e-06	2.71e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CXCL2—dilated cardiomyopathy	4.53e-06	2.71e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AGTR2—dilated cardiomyopathy	4.53e-06	2.71e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—EGFR—dilated cardiomyopathy	4.53e-06	2.71e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—RAF1—dilated cardiomyopathy	4.52e-06	2.7e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.5e-06	2.69e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	4.49e-06	2.69e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.49e-06	2.68e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—RAC1—dilated cardiomyopathy	4.49e-06	2.68e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	4.44e-06	2.66e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.44e-06	2.66e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—TNF—dilated cardiomyopathy	4.37e-06	2.61e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—EGFR—dilated cardiomyopathy	4.36e-06	2.61e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—RAF1—dilated cardiomyopathy	4.35e-06	2.6e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—RAF1—dilated cardiomyopathy	4.34e-06	2.6e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.32e-06	2.58e-05	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—EGFR—dilated cardiomyopathy	4.31e-06	2.58e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—TNF—dilated cardiomyopathy	4.31e-06	2.58e-05	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—EGFR—dilated cardiomyopathy	4.27e-06	2.56e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.27e-06	2.55e-05	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—EGFR—dilated cardiomyopathy	4.25e-06	2.54e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—RAC1—dilated cardiomyopathy	4.24e-06	2.54e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	4.23e-06	2.53e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—EGFR—dilated cardiomyopathy	4.23e-06	2.53e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.22e-06	2.52e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CD36—dilated cardiomyopathy	4.21e-06	2.52e-05	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—EGFR—dilated cardiomyopathy	4.21e-06	2.52e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Adaptive Immune System—EGFR—dilated cardiomyopathy	4.19e-06	2.51e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—EGFR—dilated cardiomyopathy	4.15e-06	2.48e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—RAC1—dilated cardiomyopathy	4.14e-06	2.48e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—EGFR—dilated cardiomyopathy	4.14e-06	2.47e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—RAF1—dilated cardiomyopathy	4.11e-06	2.46e-05	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—EGFR—dilated cardiomyopathy	4.1e-06	2.45e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.08e-06	2.44e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—RAF1—dilated cardiomyopathy	4.07e-06	2.43e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—EGFR—dilated cardiomyopathy	4.05e-06	2.42e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AGT—dilated cardiomyopathy	4.05e-06	2.42e-05	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—EGFR—dilated cardiomyopathy	4.04e-06	2.42e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—GPX1—dilated cardiomyopathy	4.02e-06	2.41e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—RAF1—dilated cardiomyopathy	4.01e-06	2.4e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—RAC1—dilated cardiomyopathy	4.01e-06	2.4e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4e-06	2.39e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—EGFR—dilated cardiomyopathy	4e-06	2.39e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—RAC1—dilated cardiomyopathy	3.97e-06	2.38e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.94e-06	2.36e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—CD36—dilated cardiomyopathy	3.92e-06	2.34e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.92e-06	2.34e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—EGFR—dilated cardiomyopathy	3.86e-06	2.31e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.86e-06	2.31e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AGT—dilated cardiomyopathy	3.83e-06	2.29e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—EGFR—dilated cardiomyopathy	3.8e-06	2.27e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—RAF1—dilated cardiomyopathy	3.8e-06	2.27e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.74e-06	2.23e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—EGFR—dilated cardiomyopathy	3.74e-06	2.23e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—RAF1—dilated cardiomyopathy	3.72e-06	2.22e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.72e-06	2.22e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.71e-06	2.22e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—RAF1—dilated cardiomyopathy	3.71e-06	2.22e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—RAC1—dilated cardiomyopathy	3.67e-06	2.19e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.67e-06	2.19e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—GPX1—dilated cardiomyopathy	3.66e-06	2.19e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—RAF1—dilated cardiomyopathy	3.63e-06	2.17e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—RAC1—dilated cardiomyopathy	3.61e-06	2.16e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—RAF1—dilated cardiomyopathy	3.61e-06	2.16e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—RAF1—dilated cardiomyopathy	3.59e-06	2.14e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—RAF1—dilated cardiomyopathy	3.57e-06	2.14e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—CD36—dilated cardiomyopathy	3.57e-06	2.13e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	3.55e-06	2.12e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—RAC1—dilated cardiomyopathy	3.54e-06	2.12e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AGT—dilated cardiomyopathy	3.53e-06	2.11e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—EGFR—dilated cardiomyopathy	3.51e-06	2.1e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—EGFR—dilated cardiomyopathy	3.51e-06	2.1e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—EGFR—dilated cardiomyopathy	3.5e-06	2.1e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.49e-06	2.09e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—RAC1—dilated cardiomyopathy	3.48e-06	2.08e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	3.46e-06	2.07e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AGT—dilated cardiomyopathy	3.45e-06	2.07e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—RAF1—dilated cardiomyopathy	3.44e-06	2.06e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—RAF1—dilated cardiomyopathy	3.42e-06	2.05e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—RAF1—dilated cardiomyopathy	3.4e-06	2.03e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AGT—dilated cardiomyopathy	3.38e-06	2.02e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—EGFR—dilated cardiomyopathy	3.36e-06	2.01e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—RAC1—dilated cardiomyopathy	3.35e-06	2.01e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—TNF—dilated cardiomyopathy	3.34e-06	2e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—EGFR—dilated cardiomyopathy	3.34e-06	2e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AGT—dilated cardiomyopathy	3.33e-06	1.99e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—RAC1—dilated cardiomyopathy	3.31e-06	1.98e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.31e-06	1.98e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—RAF1—dilated cardiomyopathy	3.3e-06	1.97e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AGT—dilated cardiomyopathy	3.21e-06	1.92e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.21e-06	1.92e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AGT—dilated cardiomyopathy	3.21e-06	1.92e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AGT—dilated cardiomyopathy	3.16e-06	1.89e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—RAF1—dilated cardiomyopathy	3.15e-06	1.88e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—RAF1—dilated cardiomyopathy	3.14e-06	1.88e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.11e-06	1.86e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—EGFR—dilated cardiomyopathy	3.1e-06	1.85e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—EGFR—dilated cardiomyopathy	2.98e-06	1.78e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—EGFR—dilated cardiomyopathy	2.98e-06	1.78e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—RAF1—dilated cardiomyopathy	2.97e-06	1.78e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—RAC1—dilated cardiomyopathy	2.9e-06	1.74e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.84e-06	1.7e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—EGFR—dilated cardiomyopathy	2.82e-06	1.69e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—RAF1—dilated cardiomyopathy	2.81e-06	1.68e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—EGFR—dilated cardiomyopathy	2.79e-06	1.67e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AGT—dilated cardiomyopathy	2.77e-06	1.66e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—EGFR—dilated cardiomyopathy	2.75e-06	1.65e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—RAF1—dilated cardiomyopathy	2.75e-06	1.64e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—RAF1—dilated cardiomyopathy	2.66e-06	1.59e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—RAF1—dilated cardiomyopathy	2.63e-06	1.58e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	2.62e-06	1.57e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—EGFR—dilated cardiomyopathy	2.61e-06	1.56e-05	CbGpPWpGaD
Dasatinib—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.57e-06	1.54e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—RAC1—dilated cardiomyopathy	2.57e-06	1.54e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	2.56e-06	1.53e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—EGFR—dilated cardiomyopathy	2.55e-06	1.53e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.55e-06	1.52e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—EGFR—dilated cardiomyopathy	2.54e-06	1.52e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—EGFR—dilated cardiomyopathy	2.49e-06	1.49e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—GPX1—dilated cardiomyopathy	2.48e-06	1.48e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—EGFR—dilated cardiomyopathy	2.48e-06	1.48e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—EGFR—dilated cardiomyopathy	2.46e-06	1.47e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AGT—dilated cardiomyopathy	2.45e-06	1.47e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—EGFR—dilated cardiomyopathy	2.45e-06	1.47e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—RAF1—dilated cardiomyopathy	2.43e-06	1.45e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CD36—dilated cardiomyopathy	2.41e-06	1.44e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—RAF1—dilated cardiomyopathy	2.4e-06	1.43e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—EGFR—dilated cardiomyopathy	2.36e-06	1.41e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—EGFR—dilated cardiomyopathy	2.35e-06	1.4e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—RAF1—dilated cardiomyopathy	2.35e-06	1.4e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—EGFR—dilated cardiomyopathy	2.33e-06	1.39e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—RAF1—dilated cardiomyopathy	2.31e-06	1.38e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	2.3e-06	1.38e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—EGFR—dilated cardiomyopathy	2.26e-06	1.35e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—RAF1—dilated cardiomyopathy	2.22e-06	1.33e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—RAF1—dilated cardiomyopathy	2.2e-06	1.31e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AGT—dilated cardiomyopathy	2.17e-06	1.3e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—EGFR—dilated cardiomyopathy	2.16e-06	1.29e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—EGFR—dilated cardiomyopathy	2.15e-06	1.29e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—EGFR—dilated cardiomyopathy	2.04e-06	1.22e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	1.98e-06	1.18e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CD36—dilated cardiomyopathy	1.93e-06	1.15e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EGFR—dilated cardiomyopathy	1.93e-06	1.15e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—RAF1—dilated cardiomyopathy	1.92e-06	1.15e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—EGFR—dilated cardiomyopathy	1.88e-06	1.13e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EGFR—dilated cardiomyopathy	1.82e-06	1.09e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—EGFR—dilated cardiomyopathy	1.81e-06	1.08e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AGT—dilated cardiomyopathy	1.74e-06	1.04e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—RAF1—dilated cardiomyopathy	1.7e-06	1.02e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—dilated cardiomyopathy	1.67e-06	9.97e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—dilated cardiomyopathy	1.64e-06	9.83e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—dilated cardiomyopathy	1.61e-06	9.63e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—dilated cardiomyopathy	1.58e-06	9.48e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	1.58e-06	9.45e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	1.54e-06	9.21e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—dilated cardiomyopathy	1.53e-06	9.12e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—dilated cardiomyopathy	1.51e-06	9.01e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	1.39e-06	8.29e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—dilated cardiomyopathy	1.32e-06	7.89e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	1.22e-06	7.3e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	1.19e-06	7.11e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—dilated cardiomyopathy	1.17e-06	6.98e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	1.07e-06	6.4e-06	CbGpPWpGaD
